The effect of propolis supplementation on cardiovascular risk factors in women with rheumatoid arthritis: A double‐blind, placebo, controlled randomized clinical trial
Phytotherapy Research · 2023
DOI: 10.1002/ptr.7996 ↗At a glance
Randomisierte kontrollierte Studie in Phytotherapy Research, 2023. Written by Mona Maddahi and 6 co-authors. Institution: Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Major MEDLINE topics: Propolis, Cardiovascular Diseases, Arthritis, Rheumatoid. Cited 21 times so far (Crossref); 77 references.
Abstract (original language)
Propolis has gained popularity in recent years because of its beneficial properties, which make it a possible preventative and therapeutic agent as well as a valuable food and cosmetic ingredient. The objective of this study was to evaluate the effects of propolis supplementation on cardiovascular risk factors in women with rheumatoid arthritis. This randomized, double‐blind, placebo‐controlled clinical trial was performed among 48 patients diagnosed with rheumatoid arthritis. Subjects were randomly assigned to placebo and intervention groups, supplemented with 1000 mg/day of propolis for 12 weeks. Cardiovascular risk factors including, high‐sensitivity C‐reactive protein (hs‐CRP), monocyte chemoattractant protein (MCP‐1), Nitric oxide, blood pressure, and lipid profile were assessed pre‐and post‐intervention. The atherogenic index of plasma value, as well as total cholesterol/high‐density lipoprotein cholesterol (HDL‐C), triglyceride/HDL‐C, and non‐HDL‐C/HDL‐C ratios, were significantly reduced in the intervention group, compared with the placebo group post‐intervention ( p < 0.05). Moreover, there was a significant reduction in the serum level of hs‐CRP in the intervention group when compared with the placebo group ( p = 0.001). Furthermore, propolis supplementation could marginally reduce MCP‐1 ( p = 0.051). These data indicate that propolis supplementation may be a promising treatment strategy for cardiovascular complications among rheumatoid arthritis patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Nutrition, Food Sciences and Clinical Biochemistry, School of Medicine, Social Determinants of Health Research Center, Gonabad University of Medical Science, Gonabad, Iran.
- Rheumatic Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of pathobiology and laboratory sciences, North Khorasan University of Medical Sciences, Bojnurd, Iran.
- Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
ORCID profiles: Mona Maddahi, Elyas Nattagh-Eshtivani, Mehdi Barati, Hamed Tabesh, Mohammad Safarian, Maryam Khosravi
Cite
APA
Maddahi, M., Nattagh-Eshtivani, E., Jokar, M., Barati, M., Tabesh, H., Safarian, M., & Khosravi, M. (2023). The effect of propolis supplementation on cardiovascular risk factors in women with rheumatoid arthritis: A double‐blind, placebo, controlled randomized clinical trial. Phytotherapy Research. https://doi.org/10.1002/ptr.7996
Vancouver
Maddahi M, Nattagh-Eshtivani E, Jokar M, Barati M, Tabesh H, Safarian M, et al. The effect of propolis supplementation on cardiovascular risk factors in women with rheumatoid arthritis: A double‐blind, placebo, controlled randomized clinical trial. Phytotherapy Research. 2023. doi:10.1002/ptr.7996
BibTeX
@article{Maddahi2023,
author = {Maddahi, Mona and Nattagh-Eshtivani, Elyas and Jokar, Mohammadhassan and Barati, Mehdi and Tabesh, Hamed and Safarian, Mohammad and Khosravi, Maryam},
title = {The effect of propolis supplementation on cardiovascular risk factors in women with rheumatoid arthritis: A double‐blind, placebo, controlled randomized clinical trial},
journal = {Phytotherapy Research},
year = {2023},
doi = {10.1002/ptr.7996}
}
EUVIMED